A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
about
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesEfficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA).Mechanisms of Jak/STAT signaling in immunity and diseaseRepeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeksIL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeuticsEffects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial.The JAK-STAT pathway: impact on human disease and therapeutic interventionUpdate in feline therapeutics: clinical use of 10 emerging therapies.Cytokine Concentrations Measured by Multiplex Assays in Canine Peripheral Blood Samples.JAK inhibitors in dermatology: The promise of a new drug class.The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.Atopic Dermatitis in Animals and People: An Update and Comparative Review.JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study.A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Developments in small animal veterinary dermatology.A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.Atopic dermatitis in cats and dogs: a difficult disease for animals and owners
P2860
Q26775111-A4CA88FE-9D44-4978-99DD-BEF5B1C8F465Q34805412-0D402B20-8385-4BCF-9667-7E06A9F75B89Q34806216-711E6874-C03F-46B9-8266-E2A2F459E430Q35194645-92A7E1E8-98E7-4DE5-A066-08C1BA0AC749Q35746839-ACFBBB8D-EA10-4338-8108-5672FF4F36DAQ35915068-49269C9B-996D-482C-B53A-B32D18D71DB0Q36533132-F37C1C8E-9331-4A25-B53A-D6161CE78F32Q36533156-062E5766-CB96-4694-9AD2-33651DB83139Q37547905-1E3566E2-47D3-49C9-9603-57481E812361Q38317993-07CDEF1D-9C5E-4ED5-8D4A-F88A455479A2Q38363411-B79700C8-EAA4-4E33-8B94-2C7F229D7E41Q38622504-9A6E5C09-E799-4548-8A17-5B490D20F9FEQ39111032-15B8D922-6B77-4969-86B2-26BCF8A3BB28Q39388632-0E884533-800C-4C21-9716-93C65D6006E7Q39413866-1B9BD4C5-56B8-482A-8F32-D14B88445C5DQ40209583-0D8F8DBF-7C4D-4B24-A7D4-AD74CD2D22DCQ41479487-6EBC6285-D2DA-4F2A-BEE5-F2EB422AD9FDQ45601105-C7617C9B-3B50-4222-8609-80C39A34D1D8Q47099145-8EE393D5-397B-4307-8A4F-9A54E5131C2EQ47422451-0BB7F6B3-F83E-47A3-8B82-BD93869BEF14Q47439880-9D3705CF-58C5-4677-B506-524B7C5D69A5Q47986677-5EFF0CBF-1E69-44E5-B622-2983CEB08ACFQ48347863-A382CDC2-4ED9-42A1-B441-72BAEA3E2A6AQ48556502-5FF7A1FC-025D-4428-B280-C0591D475688Q50185658-75D450F8-E206-4222-9B67-31BFBC7F70CDQ51486780-AC574563-C052-4872-9023-AA649D62BA8BQ54453353-BE604650-A56D-473B-8D52-671F3CA3F998Q57482859-41BDBEB2-293E-4FB2-83FB-3FDE442875E4
P2860
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@ast
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@en
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@nl
type
label
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@ast
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@en
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@nl
prefLabel
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@ast
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@en
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@nl
P2093
P2860
P356
P1476
A blinded, randomized, placebo ...... d dogs with atopic dermatitis.
@en
P2093
Dawn M Cleaver
Jezaniah-Kira S Tena
Jody A Wren
Kelly F Walsh
Michael R Stegemann
Sallie B Cosgrove
Stacey I Follis
Vickie I King
P2860
P304
587-97, e141-2
P356
10.1111/VDE.12088
P577
2013-12-01T00:00:00Z